Is there a need for emerging drugs for the acute respiratory distress syndrome?

Expert Opinion on Emerging Drugs

Volumn 19, Issue 3, 2014, Pages 323-328

  Fitzgerald, Marianne ^a   McAuley, Daniel F ^a   Matthay, Michael ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF SAN FRANCISCO   (United States)

Author keywords

Acute respiratory distress syndrome; Aspirin; IFN ; Mesenchymal stromal cells; Oncostatin M

Indexed keywords

ANIMAL; DRUG DESIGN; HUMAN; PATHOPHYSIOLOGY; RESPIRATORY DISTRESS SYNDROME, ADULT;

ANIMALS; DRUG DESIGN; HUMANS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84906821361     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2014.953052     Document Type: Review

References (47)

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967;2(7511):319-23
2. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149(3 Pt 1):818-24
3. Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307(23):2526-33
4. Thompson BT, Matthay MA. The Berlin definition of ARDS versus pathological evidence of diffuse alveolar damage. Am J Respir Crit Care Med 2013;187(7):675-7
5. Thille AW, Esteban A, Fernandez-Segoviano P, et al. Comparison of the Berlin definition for acute respiratory distress syndrome with autopsy. Am J Respir Crit Care Med 2013;187(7):761-7
6. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342(18):1334-49
7. Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol 2014;306(3):L217-30
8. Frank JA, Wray CM, McAuley DF, et al. Alveolar macrophages contribute to alveolar barrier dysfunction in ventilatorinduced lung injury. Am J Physiol Lung Cell Mol Physiol 2006;291(6):L1191-8
9. Mokart D, Guery BP, Bouabdallah R, et al. Deactivation of alveolar macrophages in septic neutropenic ARDS. Chest 2003;124(2):644-52
10. Looney MR, Nguyen JX, Hu Y, et al. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009;119(11):3450-61
11. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005;353(16):1685-93
12. Phua J, Badia JR, Adhikari NK, et al. Has mortality from acute respiratory distress syndrome decreased over time?: a systematic review. Am J Respir Crit Care Med 2009;179(3):220-7
13. Guerin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 2013;368(23):2159-68
14. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010;363(12):1107-16
15. Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009;374(9698):1351-63
16. Serpa Neto A, Cardoso SO, Manetta JA, et al. Association between use of lungprotective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: a meta-analysis. JAMA 2012;308(16):1651-9
17. Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI): a randomized placebocontrolled clinical trial. Am J Respir Crit Care Med 2006;173(3):281-7
18. Gates S, Perkins GD, Lamb SE, et al. Beta-Agonist Lung Injury Trial-2 (BALTI-2): a multicentre randomised double-blind placebo controlled trial and economic evaluation of intravenous infusion of salbutamol vs placebo in patients with acute respiratory distress syndrome. Health Technol Assess 2013;17(38):v-vi, 1-87
19. National Heart Lung; Blood Institute ACTN. Truwit JD, Bernard GR, Steingrub J, et al. Rosuvastatin for sepsisassociated acute respiratory distress syndrome. N Engl J Med 2014;370(23):2191-200
20. Thille AW, Esteban A, Fernandez-Segoviano P, et al. Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies. Lancet Respir Med 2013;1(5):395-401
21. Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014;2(8):611-20
22. Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxininduced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA 2009;22;106(38):16357-62
23. Shyamsundar M, McKeown ST, O'Kane CM, et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009;179(12):1107-14
24. Erlich JM, Talmor DS, Cartin-Ceba R, et al. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest 2011;139(2):289-95
25. Kor DJ, Talmor DS, Banner-Goodspeed VM, et al. Lung Injury Prevention with Aspirin (LIPS-A): a protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury. BMJ Open 2012;2:e001606, doi:10.1136
26. Goolaerts A, Pellan-Randrianarison N, Larghero J, et al. Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury. Am J Physiol Lung Cell Mol Physiol 2014;306(11):L975-85
27. Ware LB, Matthay MA. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol 2002;282(5):L924-40
28. Gupta N, Su X, Popov B, et al. Intrapulmonary delivery of bone marrowderived mesenchymal stem cells improves survival and attenuates endotoxininduced acute lung injury in mice. J Immunol 2007;179(3):1855-63
29. Lee JW, Krasnodembskaya A, McKenna DH, et al. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013;187(7):751-60
30. McAuley DF, Curley GF, Hamid UI, et al. Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Physiol Lung Cell Mol Physiol 2014;306(9):L809-15
31. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351(25):2590-8
32. Baba Y, Yazawa T, Kanegae Y, et al. Keratinocyte growth factor gene transduction ameliorates acute lung injury and mortality in mice. Hum Gene Ther 2007;18(2):130-41
33. Ulrich K, Stern M, Goddard ME, et al. Keratinocyte growth factor therapy in murine oleic acid-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 2005;288(6):L1179-92
34. Shyamsundar M, McAuley DF, Ingram RJ, et al. Keratinocyte growthfactor promotes epithelial survival and resolution in a human model of lung injury. Am J Respir Crit Care Med 2014;189(12):1520-9
35. Stuve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996;40(6):853-63
36. Yong VW. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Neurology 2002;59(6):802-8
37. Kraus J, Ling AK, Hamm S, et al. Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann Neurol 2004;56(2):192-205
38. Niemela J, Ifergan I, Yegutkin GG, et al. IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier. Eur J Immunol 2008;38(10):2718-26
39. Airas L, Niemela J, Yegutkin G, Jalkanen S. Mechanism of action of IFNbeta in the treatment of multiple sclerosis: a special reference to CD73 and adenosine. Ann N Y Acad Sci 2007;1110:641-8
40. Bellingan G, Maksimow M, Howell DC, et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med 2014;2(2):98-107
41. Gotts JE, Matthay MA. Treating ARDS: new hope for a tough problem. Lancet Respir Med 2014;2(2):84-5
42. Grenier A, Dehoux M, Boutten A, et al. Oncostatin M production and regulation by human polymorphonuclear neutrophils. Blood 1999;93(4):1413-21
43. Suda T, Chida K, Todate A, et al. Oncostatin M production by human dendritic cells in response to bacterial products. Cytokine 2002;17(6):335-40
44. Sodhi A, Shishodia S, Shrivastava A. Cisplatin-stimulated murine bone marrow-derived macrophages secrete oncostatin M. Immunol Cell Biol 1997;75(5):492-6
45. O'Kane CM, Elkington PT, Friedland JS. Monocyte-dependent oncostatin M and TNF-alpha synergize to stimulate unopposed matrix metalloproteinase-1/3 secretion from human lung fibroblasts in tuberculosis. Eur J Immunol 2008;38(5):1321-30
46. Grenier A, Combaux D, Chastre J, et al. Oncostatin M production by blood and alveolar neutrophils during acute lung injury. Lab Invest 2001;81(2):133-41
47. Goren I, Kampfer H, Muller E, et al. Oncostatin M expression is functionally connected to neutrophils in the early inflammatory phase of skin repair: implications for normal and diabetesimpaired wounds. J Invest Dermatol 2006;126(3):628-37